Oral RIPTAC Therapeutic Targets Y220C Mutation in p53 Protein, Inducing Cancer Cell Death

A novel therapeutic compound targets a specific mutation in the p53 protein, a development that researchers say could lead to a new strategy for treating certain cancers. The compound, referred to as a RIPTAC therapeutic, is orally bioavailable and designed to selectively kill cancer cells harboring the Y220C mutation in the p53 gene. The RIPTAC therapeutic functions by creating proximity between the mutant p53 protein and an essential protein within the cancer cell. This proximity, researchers report, induces cancer cell death. The Y220C mutation in p53 has historically been difficult to target therapeutically. The development of a RIPTAC therapeutic that can be administered orally and selectively targets cancer cells with this mutation therefore represents a potentially significant advancement.

Newsflash | Powered by GeneOnline AI
Date: April 29, 2025

Related posts:

Biomarker Testing with Next-Generation Sequencing Guides Targeted Therapies in Non-Small Cell Lung Cancer Treatment STAT Reporter Adam Feuerstein Signals Positive Sentiment in Biotechnology Sector American Lung Association Emphasizes Updated Pneumococcal Vaccine Recommendations for At-Risk Groups. Drug Channels Institute Spotlights Amazon Pharmacy’s Retail Presence, Express Scripts’ Drug Trend Report Revival

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後